New medical cannabis oil product for Swedish patients
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (“STENOCARE”) and Emerald Health Therapeutics Inc (“Emerald”) hereby announces that the first product shipment and delivery of THC-CBD Balanced medical cannabis oil has been completed on February 12, 2021 to Sweden.
STENOCARE announced on September 8, that medical cannabis oil from their supplier, Emerald, had been accepted for treatment of Swedish patients. In December 2020, the first THC oil products were delivered, and now the first THC-CBD oil products have been delivered to Sweden.
In Sweden, patients have via their doctor applied for a prescription for treatment with THC-CBD medical cannabis oil.
STENOCARE is a leading supplier of prescription-based medical cannabis products for patients, and for Sweden their Canadian supplier of medical cannabis products, Emerald, will manufacture and deliver their medical cannabis oil products.
Niels V. Olsen, anesthesiologist, D.M.Sc., at “Smärt och Psykiatri Centrum Malmö” is commenting:
“We have been applying conventional treatment protocols to patients and find it relevant to supplement with medical cannabis for selected patients”
Thomas Skovlund Schnegelsberg, CEO of STEOCARE is commenting:
“With this second type of medical cannabis oil to Sweden, we now both have a high-THC oil and a balanced THC-CBD oil product available for treatment”
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.